Open-label phase I/II clinical trial of SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with RBD-protein vaccine (FINLAY-FR-1A) in children

Open AccessPublished:November 17, 2022DOI:


      • FINLAY-FR-2 conjugate vaccine is safe and immunogenic in children 3-18 y/o.
      • The third dose with FINLAY-FR-1A (dimer RBD vaccine) increases the immune response.
      • The heterologous three doses schedule elicited specific T cell response
      • This vaccination elicits neutralizing antibodies versus delta and omicron VOC.
      • Immune response in children is non-inferior to young adults.



      To evaluate a heterologous vaccination scheme in children 3-18 y/o combining two SARS-CoV-2 r-RBD protein vaccines.


      A phase I/II open-label, adaptive and multicenter trial evaluated the safety and immunogenicity of two doses of FINLAY-FR-2 (subsequently called SOBERANA 02) and the third heterologous dose of FINLAY-FR-1A (subsequently called SOBERANA Plus) in 350 children 3-18y/o in Havana Cuba. Primary outcomes were safety (phase I) and safety/immunogenicity (phase II) measured by anti-RBD IgG ELISA, molecular and live-virus neutralization titers and specific T-cells response. A comparison with adult´s immunogenicity and predictions of efficacy were made based on immunological results


      Local pain was the unique adverse event with frequency >10%, and none was serious or severe. Two doses of FINLAY-FR-2 elicited a humoral immune response similar to natural infection; the third dose with FINLAY-FR-1A increased the response in all children, similar to that achieved in vaccinated young adults. The GMT neutralizing titer was 173.8 (CI 95% 131.7; 229.5) vs. alpha, 142 (CI 95% 101.3; 198.9) vs. delta, 24.8 (CI 95% 16.8; 36.6) vs. beta and 99.2 (CI 95% 67.8; 145.4) vs. omicron.


      The heterologous scheme was safe and immunogenic in children 3-18 y/o.

      Trial registry


      Children protection against COVID-19 is pivotal for controlling virus dissemination and reducing disease incidence. COVID-19 cases and hospitalizations among children and adolescents, firstly driven by the delta variant and recently by omicron, have risen sharply even in countries with high adult vaccination coverage (Delahoy et al., 2021; Elliott et al., 2021). This context has accelerated the clinical trials of anti-SARS-CoV-2 vaccines for children (Xia et al., 2021; Han et al., 2021; Ali et al., 2021; Frenck et al., 2021; Walter et al., 2021; Wallace et al., 2021).
      For more than 30 years the Finlay Vaccine Institute has produced tetanus toxoid-conjugated vaccines, applied to children worldwide; their safety has been extensively proved through hundreds of millions of doses (Verez-Bencomo et al., 2004; Huang and Wu., 2010). FINLAY-FR-2 (also called SOBERANA 02) immunogen is anti- SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (Valdes-Balbin et al., 2021a; 2021b). It is the unique conjugate vaccine in WHO´s vaccines pipeline (WHO COVID-19, 2021). T-cell epitopes present in tetanus toxoid were expected to promote RBD specific B- and T-cell memory, and high affinity, longstanding RBD IgG antibodies.
      SOBERANA 02 has proved its safety and immunogenicity in adults 19-80 y/o; after two doses, its efficacy was 69.7%. Combined with the third dose of FINLAY-FR-1A (also called SOBERANA Plus) (recombinant RBD dimer vaccine) in a three-dose heterologous scheme, efficacy increased to 92.0% (Toledo-Romani et al., 2022a; 2022b; 2021). In August 2021, the Cuban Regulatory Authority granted their emergency use authorization in adults, being since then extensively applied nationally for preventing COVID-19 in Cuba (CECMED, 2021).
      Here, we report the results of an open-label phase I/II clinical trial in children 3-18 y/o to evaluate the safety and immunogenicity of two doses of FINLAY-FR-2 and the third dose of FINLAY-FR-1A. We avoided a placebo-controlled trial in this age group due to ethical concerns (Dal-Ré and Caplan., 2021); alternatively, a recommended comparison (or immunobridging) with an adult´s immunogenicity was established (FDA, 2021) and the clinical efficacy was estimated based on immunological results.
      Study design
      We designed a phase I/II study, open-label, adaptive and multicenter to evaluate the safety, reactogenicity and immunogenicity of two doses of FINLAY-FR-2 and a third heterologous dose of FINLAY-FR-1A in children (3-11 y/o) and teenagers (12-18 y/o). Two interim analyses would decide interruption/continuation of the study, depending on serious adverse events (AEs) during phase I.
      Phase I was conceived in a two-step, incorporating firstly 25 children 12-18 y/o (sequence 1). The first interim report (no serious AE detected) seven days after their vaccination allowed incorporating 25 children aged 3-11 (phase 1, sequence 2 and starting phase II in 12-18 y/o (n=150). A second interim report seven days after sequence 2 (no serious AE detected) allowed starting phase II in children 3-11 y/o (n=150). (Figure 1). Detailed information on trial sites is presented in supplementary material I.
      Figure 1
      Figure 1Flow chart: recruitment, inclusion, vaccination and follow-up of 3-18 years old children in phase I/II trial.
      Children were recruited at the community level across the primary health system by medical doctors. They were included following a physical examination, parent interview and, for phase I, clinical laboratory assays. Key inclusion criteria were weight-height nutritional assessment; physical examination without alterations; clinical laboratory results within the range of reference values (only phase I) and microbiology laboratory tests. Key exclusion criteria were any acute infection, previous or current history of SARS CoV-2 infection and being a contact of a positive COVID-19 case. A detailed description of selection criteria appears in supplementary material II.
      Ethical issues
      The trial was approved by the Ethical Committee at the “Juan Manuel Marquez” Pediatric Hospital and endorsed by the Cuban National Pediatric Group. The Cuban National Regulatory Agency (Centre for State Control of Medicines and Medical Devices, CECMED) approved the trial (June10th, 2021, Authorization Reference: 05.010.21BA).
      Independent Data Monitoring Committees formed by five external members specialized on pediatric clinical practice; immunology and statistics were in charge of two interim analyses during phase I.
      The trial was conducted according to Helsinki's Declaration, Good Clinical Practice and the Cuban National Immunization Program. During recruitment, the medical investigators provided to the parents, both orally and written, all information about the vaccine and potential risks and benefits. Written informed consent was obtained from both parents; children ≥over 12 y/o should assent. The decision to participate was not remunerated.
      The National Clinical Trials Coordinating Centre (CENCEC) was responsible for monitoring the trial in terms of adherence to the protocol, to Good Clinical Practice and data accuracy.
      Trial registry: RPCEC00000374 (Cuban Public Registry of Clinical Trials and WHO International Clinical Registry Trials Platform) (IRCT, 2021).
      Products under evaluation
      FINLAY-FR-2 (RBD chemically conjugated to the carrier protein tetanus toxoid) and FINLAY-FR-1A (RBD dimer), adjuvanted in alumina hydroxide were produced at the Finlay Vaccine Institute and the Centre for Molecular Immunology, in Havana, Cuba, under GMP conditions. Both are subunit vaccines-based SARS-CoV-2 RBD, sequence Arg319-Phe541 produced in genetically modified CHO cells. Formulations are detailed in supplementary material III-Table S1.
      Product batches used: FINLAY-FR-2 (E1002S02X, E1002S02); FINLAY-FR-1A (E1001SP).
      RT-PCR SARS-CoV-2 was performed to all participants at least 72 hours before each dose. Participants with negative PCR results received the vaccine by intramuscular injections in the deltoid region. Immunization schedule: two doses of FINLAY-FR-2 and a heterologous third dose of FINLAY-FR-1A 28 days apart (immunization on days 0, 28, 56). After each immunization, participants were on-site evaluated during one hour. Medical controls visits were planned at 24, 48 and 72 hours, and on days 7, 14 and 28 after each dose. AEs were parents registered daily. Serum samples were collected on day 0 (before vaccination) and 14 days after the second and the third dose (days 42 and 70). Peripheral blood mononuclear cells were obtained before vaccination and after the third dose (day 70) in a participants’ subset of 45 children randomly selected in each age subgroup.
      Primary outcomes. Phase I: occurrence of serious AEs, measured daily during 28 days after each dose. Phase II: % of subjects with seroconversion ≥4 fold increase of IgG anti-RBD over pre-immunization, on days 42 and 70.
      Secondary outcomes. Phase I and phase II: Solicited local and systemic AEs, measured during 7 days after each dose; unsolicited AEs, measured 28 days after each dose; neutralizing antibody titers (on days 42 and 70, on a sample subset), inhibition of RBD-hACE2 interaction (on days 42, 70). Phase II: Occurrence of serious AEs, measured 28 days after each dose. Outcomes are detailed in supplementary material III).
      Outcomes and safety assessments are detailed in supplementary material IV and V.
      Immunogenicity assessment
      Immunogenicity was evaluated by: a) quantitative ultramicro ELISA (UMELISA SARS-CoV-2 anti- RBD; b) competitive ELISA determined the inhibitory capacity of antibodies for blocking the RBD-hACE2 interaction, expressed as % inhibition and molecular virus neutralization titer (mVNT50); c) conventional virus neutralization titer (cVNT50) vs. D614G, alpha, beta, delta and omicron variants; d) RBD-specific T-cell response producing IFN-γ and IL-4. Immunogenicity assessment and techniques are described in supplementary material VI. All immunological evaluations were performed by external laboratories from the Centre for Immunoassays, Centre of Molecular Immunology and National Civil Defense Research Laboratory. T cell response was evaluated at Finlay Vaccine Institute. A detailed description of immunogenicity assessments and techniques are described in supplementary material VI.
      Children Convalescent Serum Panel
      A Cuban children's convalescent serum panel (CCCSP) was made with sera from 82 patients (3-18 y/o) recovered from COVID-19. Detailed information about panel composition and immune characterization is presented in supplementary material VII
      Statistical analysis
      For phase I, the calculation of sample size was done considering a two-sided 95% confidence interval for one proportion with a width equal to 0.09 to estimate a serious AE rate <1%. For phase II a similar method was used to estimate a seroconversion around 50%, with a lower bound of the confidence interval >30% (trial hypothesis) and a dropout of 20%. This resulted in a sample size of 350 subjects (including subjects from phase I). Detailed statistical tools, procedures and definitions are presented in supplementary material VIII.
      Figure 1 and Table 1 describe the study design and demographic characteristics of the participants. From 11th June to 14th July 2021, 426 children (3-18 y/o) were recruited, 350 that accomplished selection criteria were included, and 306 completed the study. There was a balanced ratio on sex and ethnicity; mean age was 11.3 years (SD 4.5).
      Table 1Demographic characteristics of subjects included in the clinical trial
      Age groups
      3-11 years12-18 yearsTotal 3-18 years
      Female80 (45.7%)83 (47.4%)163 (46.6%)
      Male95 (54.3%)92 (52.6%)187 (53.4%)
      Skin colour
      White122 (69.7%)116 (66.3%)238 (68.0%)
      Black9 (5.1%)11 (6.3%)20 (5.7%)
      Multiracial44 (25.1%)48 (27.4%)92 (26.3%)
      Age (years)
      Mean (SD)7.4 (2.5)15.1 (2.1)11.3 ± 4.5
      Median (IQR)8.0 (5.0)15.0 (4.0)11.5 ± 7.0
      Range3; 1112;183-18
      Weight (kg)
      Mean (SD)29.4 (10.1)54.7 (9.0)42.0 ± 15.9
      Median (IQR)27.5 (14.0)55.0 (13.0)43.0 ± 27.7
      Range13.0; 58.032.0; 80.013.0; 80.0
      Height (cm)
      Mean (SD)129.1 (17.2)164.3 (9.6)146.7 ± 22.5
      Median (IQR)131.0 (26.0)164.0 (13.0)151.0 ± 34.0
      Range92; 172142; 19092-190
      BMI (kg/m2)
      Mean (SD)17.0 (2.0)20.2 (2.3)18.6 ± 2.7
      Median (IQR)16.7 (2.7)19.9 (3.8)18.3 ± 4.1
      Range13.2; 22.814.6; 25.513.2-25.5
      Data are n (%) unless otherwise specified. Mean (SD)=Mean ± Standard Deviation. Median (IQR)=Median ± Interquartile Range. BMI=Body mass index. Range= (Minimum; Maximum)
      Phase I started by vaccinating 25 children 12-18 y/o with FINLAY-FR-2; the first interim analysis done seven days after vaccination indicated the absence of serious AEs. In consequence, the trial proceeded to phase I sequence 2, incorporating 25 children aged 3-11 and 150 children aged 12-18 of phase II. The second interim analysis showed no serious AE in children 3-11 y/o (sequence 2); the trial completed phase II vaccinating 150 children 3-11 y/o with FINLAY-FR-2 first dose.
      During the vaccination scheme, 86 children (53.1%) suffered at least one AE; the frequency was higher (60%) in teenagers than in young children (46.3%). Severe and serious vaccine-associated AEs (VAAE) did not occur (Table 2). Local AE predominated; the most common was local pain (47.7%), and all others had frequencies <5%; only 1.1% reported fever (Table 3). More than 90% of AEs were classified as mild and lasted ≤72 hours, and 88.5% were associated with vaccination (Table 3, Supplemental Material IX-Table S2). AEs were more frequent after the first dose than after the second and the third dose (Supplemental Material IX-Table S3). Few unsolicited adverse events were recorded (Supplemental Material IX-Table S4). Haematology and blood chemistry were studied on days 0 (before first dose), 7 and 70 (14 days after the third dose). Data were separately evaluated in two age groups (3-11 y/o, N=25 and 12-18 y/o, N=24, from phase 1). No clinically relevant changes were observed in hematology and blood chemistry analyses.
      Table 2General characteristics of adverse events
      Age groups
      3-11 years12-18 yearsTotal
      Subjects with some AE81 (46.3%)105 (60.0%)186 (53.10%)
      Subjects with some VAAE76 (43.4%)101 (57.7%)177 (50.6%)
      Subjects with some Serious AE0 (0.0%)1 (0.6%)*1 (0.3%)
      Subjects with some Serious VAAE0 (0.0%)0 (0.0%)0 (0.0%)
      Subjects with some Severe AE0 (0.0%)0 (0.0%)0 (0.0%)
      Subjects with some Severe VAAE0 (0.0%)0 (0.0%)0 (0.0%)
      Total of Adverse Events141182323
      VAAE126 (89.4%)160 (87.9)286 (88.5%)
      Serious VAAE0 (0.0%)0 (0.0%)0 (0.0%)
      Severe VAAE0 (0.0%)0 (0.0%)0 (0.0%)
      Data are n (%). AE=Adverse Event. VAAE=Vaccine-Associated Adverse Event;
      * Serious AE: Dengue required hospitalization.
      Table 3Frequency of solicited adverse events
      Age groups
      3-11 years12-18 yearsTotal
      Subjects with some AE81 (46.3%)105 (60.0%)186 (53.10%)
      Subjects with solicited local AE
      Any74 (42.3%)98 (56.0%)172 (49.1%)
      Local pain69 (39.4%)98 (56.0%)167 (47.7%)
      Swelling9 (5.1%)2 (1.1%)11 (3.1%)
      Local warm4 (2.3%)0 (0.0%)4 (1.1%)
      Erythema5 (2.9%)1 (0.6%)6 (1.7%)
      Induration5 (2.9%)1 (0.6%)6 (1.7%)
      Subjects with solicited systemic AE
      Any5 (2.9)4 (2.3)9 (2.6)
      General discomfort1 (0.6%)3 (1.7%)4 (1.1%)
      Fever (≥38 C)2 (1.1)1 (0.6)3 (0.9)
      Low-grade fever (<38 C)4 (2.3)1 (0.6)5 (1.4)
      Data are n (%) unless otherwise specified. AE=Adverse Event
      Before vaccination, 97.1 % of children were negative for anti-RBD antibodies, median anti-RBD IgG was 1.95 UA/mL (25th-75th percentile 1.95; 1.95). Two doses of FINLAY-FR-2 induced seroconversion in 96.2% of participants (CI 95% 93.5; 98.0), and satisfied the trial hypothesis (>50% of seroconversion with a lower boundary of the two-sided 95% confidence interval >0.3) (Table 4). Global seroconversion index was 27.8; the median anti-RBD IgG was 57.0 UA/mL (25th-75th percentile 29.8; 153.4 (Table S5). By age subgroup, seroconversion was 99.4% (CI 95% 96.5; 99.9) in children 3-11 y/o and 93.1% (CI 95% 88.0; 96.5) in 12-18 y/o (Supplemental Material IX-Table S5). The heterologous third dose with FINLAY-FR-1A increased seroconversion to 100% and seroconversion index to 154.5; anti-RBD IgG titers also increased significantly (p<0.005) to 325.7 UA/mL (25th-75th percentile 141.5; 613.8) (Table 4). Specific antibody response was higher than the elicited by natural infection, evaluated in Cuban children's convalescent panel (anti-RBD IgG median 11.5; 25th-75th percentile 5.3; 24.2).
      Table 4Humoral immune response induced after two doses of FINLAY-FR-2 and the third heterologous dose with FINLAY-FR-1A
      Age group 3-18 y/oCCCSP
      Post-2nd dosePost-3rd dose
      Anti-RBD IgG seroconversion rateN (%)305/317 (96.2)305/305 (100.0)*N.D
      95% CI93.5; 98.099.8; 100.0
      Anti-RBD IgG AU/mLMedian57.0325.7*11.5
      25th-75th29.8; 153.4141.5; 613.85.3; 24.2
      Seroconversion indexMedian27.8154.5*N.D
      25th-75th14.3; 69.067.2; 260.9
      RBD:hACE2 Inh%Median67.492.4*20.8
      25th-75th42.1; 86.988.3; 93.510.9; 40.8
      95% CI168.4; 233.91105.5; 1438.825.3; 48.9

      vs D614G
      95% CI20.2; 34.5123.0; 204.06.8; 12.5
      Footnote: t0 or baseline anti-RBD IgG was 1.95 (25th-75th percentile: 1.95; 1.95). ND: Not determined. Anti-RBD IgG seroconversion rate: % of subjects with seroconversion (CI 95%). Seroconversion index: fold-increase of IgG concentration respect to baseline (median; 25th-75th percentile). AU/mL=anti-RBD IgG concentration expressed in arbitrary units/mL. RBD:hACE2 Inh%: RBD:hACE2 inhibition % at a serum dilution 1/100. mVNT50: molecular virus neutralization titer. cVNT50: conventional live-virus neutralization titer. GMT=Geometric Mean Titer. * p<0.005 versus Post - 2nd dose McNemar test (anti-RBD IgG seroconversion %), Wilcoxon Signed Ranks test (anti-RBD IgG AU/mL, RBD:hACE2 Inh%) or Paired Student t- test (mVNT50, cVNT50, log-transformed). CCCSP=Cuban children's convalescent serum panel
      The capacity of anti-RBD IgG for blocking RBD- hACE2 interaction after two doses of FINLAY-FR-2 was 67.4 % (25th-75th percentile 42.1; 86.9) and the mVNT50 was 198.5 (CI 95% 168.4; 233.9); both increased significantly (p<0.005) after the third dose to 92.4 % (25th-75th percentile 88.3; 93.5) and 1261 (CI 95% 1105,5; 1438.8) respectively (Table 4). These values were higher among the youngers (3-11 y/o) after the second dose, but were similar in both age subgroups after the third dose (Supplemental Material IX-Table S5). After both two and three doses mVNT50 was higher than after natural infection.
      After two doses of FINLAY-FR-2 the neutralizing titer versus D614G variant was higher (GMT 26.4 CI 95% 20.2; 34.5) than the children convalescent panel value (GMT 9.2 CI 95% 6.8; 12.5); and the third dose significantly (p<0.005) boosted the response to GMT 158.4 (CI 95% 123.0; 204.0) (Table 4). The neutralizing titer versus the variants alpha, beta and delta was evaluated in 48 children; 100% had neutralizing antibodies vs. alpha and delta; 97.9% vs. beta. cVNT50 GMT was 173.8 (CI 95% 131.7; 229.5) vs. alpha, 142 (CI 95% 101.3; 198.9) vs. delta and 24.8 (CI 95% 16.8; 36.6) vs. beta; (a 2.2-fold decrease for delta and 7.0-fold decrease for beta compared to D614G). Additionally, a subset of 33 paired samples was evaluated also vs. omicron variant, showing a neutralization titer of 99.2 (CI 95% 67.8; 145.4) (Table 5).
      Table 5Conventional live-virus neutralization titers against SARS-CoV-2 variants alpha, delta, beta and omicron.
      D614GAlphaDeltaBetaOmicron BA.1
      95% CI131.7; 229.5101.3; 198.954.8; 107.716.8; 36.6
      95% CI120.2; 239.786.7; 184.847.4; 110.612.7; 29.767.8; 145.4
      Sera from 48 children vaccinated with complete schedule (two doses FINLAY-FR-2 + one dose FINLAY-FR-1A, 28 days apart) were evaluated against D614G, alpha, delta and beta variants. Of them, 33 paired-samples were evaluated also vs omicron. cVNT50=conventional live-virus neutralization titer. GMT=Geometric Mean Titer. 95% CI= 95% Confidence Interval. * p<0.005 Paired Student t test (cVNT50, log-transformed) respect to D614G variant.
      There was a good correlation among all humoral immunological variables. Predictive cut-off for attaining cVNT50 over 50 was estimated by ROC curve as: 192.2 AU/ml for IgG concentration, 87.1% for the inhibition of RBD:hACE2 and 427 for mVNT50 (Supplemental Material X-Table S6, Figure S1)
      RBD-specific T cell response in a subset of 45 participants fully vaccinated was determined by measuring IFN-γ and IL-4 expression in peripheral blood mononuclear cells. The number of IFN-γ and IL-4 secreting cells was statistically higher (p<0.001) than their baseline levels (Figure 2).
      Figure 2
      Figure 2IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of FINLAY-FR-2 and a heterologous third dose (on day 56) of FINLAY-FR-1A. p value represents the statistic differences as indicated.
      The safety and immune response in children were compared with young adults (aged 19-39) vaccinated in phase I and phase II studies with the same vaccine's regimen, as recommended by FDA, 2021. Safety profile was similar in both (Supplemental Material X-Table S7, S8, Figure S2). An immunobridging analysis was performed for anti-RBD IgG, mVNT50 and cVNT50 between children and young adults. IgG elicited after two doses of FINLAY-FR-2 was 57.0 UA/ml (25th-75th percentile 29.8; 153.4), while for young adults it was 46.4 (25th-75th percentile 17.4; 108.8); after the heterologous third dose of FINLAY-FR-1A these values increased to 325.7 (25th-75th percentile 141.5; 613.8) in children and 228.0 (25th-75th percentile 95.8; 394.3) in young adults. mVNT50 was 198.5 (IC 95% 168.4; 233.9) in children after the second dose and 1261.2 (IC 95% 1105.5; 1438.8) after the third; in young adults were 94.9 (IC 95% 75.0; 120.2) and 503.7 (IC 95% 432.6; 586.6) after two and three doses (Figure 3). We found significant differences (p<0.05) for IgG and mVNT50 between 3-18 y/o children and 19-39 y/o young adults; higher values were obtained in children after both the second and the third dose. Viral neutralization titers after the second dose were measured at different time points in children and young adults (on day 42 in children and day 56 in young adults), making their comparison only approximate.
      Figure 3:
      Figure 3Immunobridging comparison of humoral immune response elicited in children (3-18 y/o) respect to young adults (19-39 y/o from Phase I and II clinical trials), after two doses of FINLAY-FR-2 (day 42) and the third dose of FINLAY-FR-1A (day 70). A) anti-RBD IgG median (25th-75th percentile); B) mVNT50 GMT (CI 95%); C) cVNT50 GMT (CI 95%). Bleeding was on day 42 and 70 (14 days after the second and third dose), except for cVNT50 adults after the second dose was on day 56. Mann-Whitney U test (anti-RBD IgG AU/mL) or Student t-test (mVNT50, cVNT50, log-transformed). p value represents the statistic differences as indicated
      The non-inferiority analysis was performed with cVNT50 data, following FDA recommendation (FDA, 2021). After three doses (on day 70), cVNT50 in children was 158.4 (CI 95% 123.0; 204.0) and 122.8 (80.2; 188.0) for young adults (n=43, data available) (Figure 3). The immune response in 3-18 y/o, as well as in age subgroups 3-11 y/o and 12-18 y/o was non-inferior to that observed in 19-39 y/o young adults. The cVNT50 GMT ratio 14 days after the third dose was 1.25 (CI 95% 0.77; 2.02) (Table 6) for children 3-18 y/o respect to adults, which met the non-inferiority criterion (i.e., a lower boundary of the two-sided 95% confidence interval of >0.67). Also, both age subgroups (3-11 y/o and 12-18 y/o) met the non-inferiority criterion.
      Table 6Immunobridging of cVNT50 in children and young adults after heterologous scheme (two doses of FINLAY-FR-2 and the third heterologous dose of FINLAY-FR-1A)
      Age groupNo. of participantscVNT50

      GMT (95% CI)
      Geometric mean ratio (95% CI) vs. 19 to 39 y/o
      19-39 y/o43127.0 (89.6; 179.80)
      3-18 y/o131158.4 (123.0; 204.0)1.25 (0.77; 2.02)
      3-11 y/o66181.6 (120.6; 273.3)1.43 (0.80; 2.54)
      12-18 y/o65137.9 (101.8; 186.9)1.08 (0.68; 1.73)
      GMT and two-sided 95% confidence intervals were calculated by exponentiating the mean logarithm of the titers and the corresponding confidence intervals (based on the Student's t distribution). The geometric mean ratio and two-sided 95% confidence intervals were calculated by exponentiating the mean difference of the logarithms of the titers (in children/adolescents cohorts minus the 19-39-year-old cohort) and the corresponding confidence intervals (based on the Student's t distribution). The non-inferiority criterion was met, since the lower boundary of the two-sided confidence interval for the geometric mean ratio was greater than 0.67.
      Based on immunogenicity data of vaccinated children and the immune response to natural infection (children convalescent panel), a prediction of clinical efficacy was estimated through a regression linear model. By using cVNT50 as the predictive variable, the estimated efficacy versus D614G is 91.3% (CI 95% 84.6; 95.1) after two doses and 97.4 % (IC 95% 91.5; 99.2) after three doses (Figure 4).
      Figure 4
      Figure 4Prediction of clinical efficacy in children from the correlation between antibody responses and efficacy rate. Panels display correlation of cVNT50 neutralization and ratios, respectively for seven vaccines in adults; two doses of FINLAY-FR-2 (represented as SOBERANA 02), and the heterologous three doses adding FINLAY-FR-1A (represented as SOBERANA Plus) in children. The y-axis is estimated log risk ratio reported on the vaccine efficacy scale. The x-axis is log ratio of the peak geometric mean neutralization at 7-28 days post-vaccination, relative to human or children convalescent sera.
      This study describes, for the first time, the safety and immunogenicity in children 3-18 y/o of two doses of FINLAY-FR-2, followed by a third heterologous dose of FINLAY-FR-1A. The frequency of local and systemic AE was 49.0% and 2.6% respectively, lower than after mRNA COVID-19 vaccination. After two doses, BNT162b2 reported 86.0% and 66.0 of children 12-15 y/o with local and systemic AEs while mRNA-1273 reported 94.2% and 68.3% (aged 12-17 y/o) respectively. In our study, local pain was reported by the 51.4% of children aged 12-18 y/o after the first dose, 17% after the second and 17.3% after the third one. BNT162b2 and mRNA-1273 vaccine in adolescents reported 86.0% and 94.2% with local pain after the first dose; and 79.0% and 92.4% after the second, respectively. FINLAY-FR-2 and FINLAY-FR-1A caused general discomfort (the most frequent systemic AE) only in 1.7% of children 12-18 y/o, while mRNA vaccines provoked fatigue, headache, chills, muscle pain or fever in 10-68.5% of adolescents (Frenck et al., 2021; Ali et al., 2021). In children aged 3-11 local pain was the unique AE with frequency >10% during this study; children aged 5-11 vaccinated with BNT162b2 reported local pain (74.0%), redness (19.0%), swelling (15.0%), fatigue (39.0%) and headache (28.0%) (Walter et al., 2021). Myocarditis and pericarditis have been reported in adolescents after mRNA COVID-19 vaccination (Oster et al., 2022; Marshall et al., 2021); these AEs were not observed here.
      The comparison of the humoral immune response elicited by vaccination with the elicited by natural infection has been a useful tool for the development of several anti-SARS-CoV-2 vaccines (Keech et al., 2020; Yang et al., 2021). Two shots of FINLAY-FR-2 every 28 days in children induced a robust humoral response, with higher levels of antibodies and similar neutralizing capacity of the elicited by natural infection. The third dose of FINLAY-FR-1A boosted both the production of antibodies and their neutralizing capacity, surpassing the immune response in convalescent children, as had been previously observed in clinical trials in adults (Toledo-Romani et al., 2022a; 2022b).
      The induction of specific T-cell response is critical for the protection of viral infections. The heterologous three doses schedule in children developed a balanced activation of IFN-γ and IL-4-secreting cells from PBMC, indicating a mixed Th1/Th2 response, as reported in adults after the same vaccination scheme (Toledo-Romani et al., 2022a).
      The SARS-CoV-2 variants of concern alpha, beta, delta, and recently, omicron have modified the pandemic landscape worldwide (Fontanet et al., 2021). Here, we report the capacity of anti-RBD antibodies for neutralizing alpha, beta, delta and omicron variants, with a fold-reduction of 2.2 for delta and 7.0 for beta compared to D614G, as we found in adults (Toledo-Romani et al., 2022b). In an independent study from the “Pedro Kourí” Tropical Medicine Institute in Havana, sera from 20 adults (vaccinated with the same vaccine regimen) neutralized the omicron variant (Portal-Miranda 2022; Carles, 2022).
      We conducted this clinical trial during the delta wave, the worst period of the Cuban epidemic (Rodriguez; 2021); in such a context and due to ethical reasons, a placebo-controlled clinical trial was not ethical and this is the main limitation of the study. Lacking a control group, two analytical tools complemented the study: immunobridging with the immune response in young adults previously vaccinated during clinical trial with the same vaccination schedule (no concurrent reference population) as recommended by FDA, 2021; and prediction of clinical efficacy based on immunological response (Khoury et al., 20211; Kristen et al., 2021). Firstly, we found a non-inferior response for the GMT ratio of SARS-CoV-2 cVNT50 after the three-dose scheme in participants 3-11 and 12-18 y/o relative to a 19-39 y/o reference population (no concurrent). The comparison met the non-inferiority criterion with a ratio of 1.43 (CI 95% 0.8-2.54) for 3-11 y/o and 1.08 (CI 95% 0.68-1.73) for 12-18 y/o, satisfying FDA recommendations (FDA, 2021) (a lower boundary of the two-sided 95% confidence interval of >0.67). Similar analyses have been reported by BNT162b2 and mRNA-1273 vaccines using 19-25 y/o as reference population (Walter et al., 2022; Ali et al., 2021). Based on published results, we considered young adults as immunocompetent up to 39 years (Lopez-Sejas 2016; Ventura et al., 2017; Thapa and Farber 2019); this increased the number of cVNT50 data for comparison in the reference population.
      Secondly, a prediction of clinical efficacy based on immunological response has been advanced for other vaccines (Khoury et al., 20211; Kristen et al., 2021). Using this model, for adults aged 19-80 we anticipated a clinical efficacy between 58% and 87% after the first two doses and between 81% and 93% after the three-dose scheme versus the D614G variant (Toledo-Romani et al., 2022b). These results were confirmed during a phase III clinical trial reporting a 69.7% of efficacy for the two-dose schedule of FINLAY-FR-2 and 92.0 % for the heterologous three-dose schedule during the beta period (Toledo-Romani et al., 2021). Here, the model predicts 91.3% clinical efficacy after two doses of FINLAY-FR-2 and 97.4% after the third dose of FINLAY-FR-1A in children, versus the D614G strain.
      Starting children vaccination at 2 y/o is key for controlling the pandemic, cutting the transmission and reducing the emergence of new VOCs (Petersen and Buchy, 2021). The safety and immunological results reported here supported the emergency use authorization of FINLAY-FR-2 and FINLAY-FR-1A as a heterologous scheme for children between 2-18 y/o. A massive immunization campaign started on 5th September 2021; fully vaccinating 1.8 million Cuban children (96% of 2-18 y/o Cuban population (Reed, 2022; Augustin, 2022). These results support public health vaccination strategies, providing children as young as two years a safe and effective vaccine scheme to prevent COVID-19.
      This work was supported by the Finlay Vaccine Institute, BioCubaFarma and the National Funds for Sciences and Technology from the Ministry of Science, Technology and Environment (FONCI-CITMA-Cuba, contract 2020-20).
      Declaration of Interests
      The authors R.P.G, Y.R.D, C.R.I, L.C.H. M.P.B, D.V.M, N.P.P, C.V.S, A.P.D, E.G.O, Y.C.E, J.C.F.P, M.S.M, M.D.E, J.M.E.P, Y.I.H, M.E.T.R declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      The authors B.P.M, M.R.G, B.S.R, L.M.R.N, R.P.N, R.G.M, T.H.G, T.F.B, I.C.Q, S.F.C, Y.C.R, D.S.M, Y.G.V, Y.V.B, D.G.R, V.V.B work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but haven't received an honorarium for this paper.
      B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R. and V.V.B., have filed patent applications related to the vaccine FINLAY-FR-2.
      D.D and A.B work at Pasteur Institute of Iran and are co-developer of the vaccines
      We especially thank all the parents and children for participating in the clinical trial. We recognize the contribution of all the medical and nurse staff at clinical sites. We thank Dr. Lila Castellanos for scientific advice.
      Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med 2021; 385: 2241-51. doi: DOI: 10.1056/NEJMoa2109522
      Augustin Ed . Cuba leads the world in vaccinating children as young as two against Covid. The Guardian. February 1st, 2022. (Accessed February 17th, 2022)
      Carles Zerquera JM. Cuban´s vaccines against Omicron. Rapid response to BMJ 2022; 376 doi:; January 29th, 2022 Available in: (Accessed February 17th, 2022)
      CECMED Cuban National Regulatory Agency. Resolution 144/2021. Authorization for emergency use of SOBERANA02 in adults. 2021 (Accessed November 17th; 2021)
      Dal-Ré R, Caplan A. Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical? Clin Microbiol Infect 2021;27:1565-67. doi: 10.1016/j.cmi.2021.08.005
      Delahoy M, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255–60. doi: 10.15585/mmwr.mm7036e2
      Earle K, Ambrosino D, Andrew Fiore-Gartland; Golblatt D, Gilbert PB, et. al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423–28. doi:
      Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science 2022; doi: 10.1126/science.abn8347
      FDA. Vaccines and Related Biological Products Advisory Committee Meeting. June 10, 2021. Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19 for Use in Pediatric Populations. 2021 (Accessed September 14th, 2021)
      Fontanet A, Autran B, Lina B, Kieny MP, Abdool Karim SS, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 2021; 397: 952–54. doi:
      Frenck R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021;385: 239–50. doi: 10.1056/NEJMoa2107456
      Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect. Dis 2021;21:1645-53. doi:
      Huang YL, Wu CY. Carbohydrate-based vaccines: challenges and opportunities. Expert Rev Vaccines 2010;9:1257–74 doi: 10.1586/erv.10.120
      IRCT International Register Clinical Trials. Identifier RPCEC00000374. Phase I-II study, sequential during phase I, open-label, adaptive and multicenter to evaluate the safety, reactogenicity and immunogenicity of a heterologous two-dose schedule of the prophylactic anti-SARS- CoV-2 vaccine candidate, FINLAY-FR- 2 and a dose of FINLAY-FR-1A, in Cuban children and adolescents. (COVID-19). (Accessed December 1st, 2021)
      Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle. N Engl J Med 2020;383: 2320-32. doi:
      Khoury DS, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J, et. al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 2021; 27:1205–11. doi:
      Lopez-Sejas N, Campos C, Hassouneh F, Sanchez-Correa B, Tarazona R, Pera A, Solana R. Effect of CMV and Aging on the Differential Expression of CD300a, CD161, T-bet, and Eomes on NK Cell Subsets. Front Immunol 2016;7:1-13. doi: 10.3389/fimmu.2016.00476
      Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Stewart JC. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics 2021;148:2-11. doi e2021052478
      Oster ME, Shay DK, Su JR, Gee J, Creech B, Broder KR et al. Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022;327:331-340. doi:10.1001/jama.2021.24110
      Petersen E, Buchy P. Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. Int. J Infectious Diseases 2021;106:429–430 doi:
      Portal-Miranda JA. Las vacunas cubanas generan anticuerpos ante ómicron: Ese éxito no puede llevarnos a la confianza. 2022 (Accessed January 26th, 2022)
      Reed G. Cuban COVID-19 Vaccines for Children: Rinaldo Puga MD MS Interview. MEDICC Review 2022; 24:14-8 doi:
      Rodriguez A. Virus slams Cuba as it races to roll out its new vaccines. ABC News, July 21th, 2021. (Accessed February 17th, 2022)
      Thapa P, Farber D. The Role of the Thymus in the Immune Response. Thorac Surg Clin, 2019; 29:123-131  doi: 10.1016/j.thorsurg.2018.12.001
      Toledo-Romani ME, Garcia-Carmenate M, Valenzuela-Silva C, Baldoquin-Rodriguez W, Martínez-Pérez M, Rodríguez-Gonzalez MC, et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANAPLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial. MedRxiv 2021
      Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C. et al. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med 2022b; doi:
      Toledo-Romani ME, Verdecia-Sánchez L, Rodriguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno et al. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Vaccine 2022a; 40: 4220–4230
      Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F et al. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Cent Sci 2021a;7:757−67. doi:
      Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernandez S, Rodriguez L, Sanchez-Ramírez B et al. SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity. ACS Chem Biol 2021b;16:1223–33. doi:
      Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up‑regulation. Clin Mol Allergy 2017; 15:21 doi:
      Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L et. al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;305: 522-525 doi: 10.1126/science.1095209
      Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain M, Moulia D et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years—United States, May 2021. MMWR Morb Mortal Wkly Rep 2021;70:749–52. doi:
      Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med 2022;386:35-46 doi: 10.1056/NEJMoa2116298
      WHO COVID-19 – Landscape of novel coronavirus candidate vaccine development worldwide., 2021 (accessed December 29th, 2021)
      World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI). 2nd Edition. Geneva: WHO; 2019. ISBN: 9789241516990 2019 (Accessed June 17th, 2021)
      Xia S, Zhang YT, Wang Y, Wang H, Yang Y, Fu-Gao G et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis 2022;22:196-208. doi: 10.1016/S1473-3099(21)00462-X
      Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21:1107-11. doi:

      Appendix. Supplementary materials